🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Guangdong Raynovent Biotech clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Guangdong Raynovent Biotech as lead sponsor. Synced 26 Sep 2026
10Current trials
2Recruiting now
6Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Guangdong Raynovent Biotech is the lead sponsor of 10 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are RAY1225, Atorvastatin Calcium and Digoxin. The most-studied condition is Obesity.

ClinicalTrials.gov trials by status

  • Recruiting220%
  • Not yet open330%
  • Active, closed550%

Trials by phase

  • Phase 3550%
  • Phase 2330%
  • Phase 1220%
01

Clinical trials sponsored by Guangdong Raynovent Biotech

10 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study of RAY1225 in Participants With Obesity
NCT06254261 · ClinicalTrials.gov ↗ · Obesity
Drug: RAY1225
Phase 2 Recruiting 2024-02 China
Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight
NCT06893016 · ClinicalTrials.gov ↗ · Obesity
Drug: RAY1225
Phase 3 Recruiting 2025-06 China
A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants
NCT07460284 · ClinicalTrials.gov ↗ · Basic Science
Phase 1 Not yet open 2026-03 China
A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes
NCT07139548 · ClinicalTrials.gov ↗ · T2DM
Phase 3 Not yet open 2025-08 China
A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
NCT07139535 · ClinicalTrials.gov ↗ · T2DM
Drug: RAY1225
Phase 3 Not yet open 2025-08 China
A Study of RAY1225 in Participants With Type 2 Diabetes
NCT06254274 · ClinicalTrials.gov ↗ · T2DM (Type 2 Diabetes Mellitus)
Drug: RAY1225
Phase 2 Active, closed 2024-02 China
Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A
NCT07229807 · ClinicalTrials.gov ↗ · Influenza a
Phase 3 Active, closed 2025-11 China
A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)
NCT05692492 · ClinicalTrials.gov ↗ · Nonalcoholic Steatohepatitis (NASH)
Phase 2 Active, closed 2023-06 China
Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A
NCT07229820 · ClinicalTrials.gov ↗ · Influenza A
Phase 3 Active, closed 2025-11 China
Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin
NCT07362030 · ClinicalTrials.gov ↗ · Obesity
Phase 1 Active, closed 2025-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Guangdong Raynovent Biotech trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Guangdong Raynovent Biotech trials

7 conditions
Obesity3T2DM2T2DM (Type 2 Diabetes Mellitus)1Basic Science1Influenza a1Nonalcoholic Steatohepatitis (NASH)1Influenza A1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China102

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Obesity

SponsorTrials
Eli Lilly and Company39
Novo Nordisk39
Amgen7
China-Japan Friendship Hospital6
Kailera5
Innovent Biologics (Suzhou)5
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School4
Hangzhou Sciwind Biosciences4
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics3
Peking University Third Hospital3

Sponsors with the most current trials registered for this condition.

06

Questions about Guangdong Raynovent Biotech trials

How many clinical trials does Guangdong Raynovent Biotech sponsor?

Guangdong Raynovent Biotech is the lead sponsor of 10 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Guangdong Raynovent Biotech trials recruiting?

Yes. 2 of its 10 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Guangdong Raynovent Biotech testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are RAY1225 (6), Atorvastatin Calcium (1), Digoxin (1), Metformin (1) and Semaglutide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.